Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, Matsumoto K, Taketani Y
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Japan.
Cancer. 1998 Oct 15;83(8):1555-60.
Patients with epithelial ovarian carcinoma upstaged from Stage I/II to Stage IIIC based on lymph node involvement are known to have poor prognoses. The authors investigated whether systematic aortic and pelvic lymphadenectomy would affect the prognoses of these patients.
During the period 1987-1996, 103 patients in Stage I-III underwent optimal cytoreductive surgery with systematic aortic and pelvic lymphadenectomy at initial surgery. All patients except for those in Stage IA received adjuvant cisplatin-based chemotherapy after surgery. Of 67 patients with intraperitoneal tumors limited to the pelvis, 14 were upstaged to Stage III based on lymph node positivity (Group A). The authors compared the survival of Group A patients with that of 53 patients who had intraperitoneal tumors limited to the pelvis and negative lymph nodes (Group B), and also with that of 36 patients who had intraperitoneal tumors beyond the pelvis irrespective of lymph node status (Group C).
The 5-year survival of Group A patients in Stage III based only on lymph node positivity had fairly good survival, although it was not significantly different from that of Group B patients in Stage I/II (84% vs. 96%, P=0.107). Group A had much better 5-year survival than Group C patients who were considered to be Stage III because they had intraperitoneal tumors beyond the pelvis (84% vs. 26%, P=0.042).
Relatively good survival was observed for patients with intraperitoneal tumors limited to the pelvis and lymph node involvement who underwent systematic aortic and pelvic lymphadenectomy.
已知上皮性卵巢癌患者若因淋巴结受累从Ⅰ/Ⅱ期进展至ⅡIC期,其预后较差。作者调查了系统性主动脉旁和盆腔淋巴结清扫术是否会影响这些患者的预后。
在1987年至1996年期间,103例Ⅰ - Ⅲ期患者在初次手术时接受了最佳肿瘤细胞减灭术及系统性主动脉旁和盆腔淋巴结清扫术。除ⅠA期患者外,所有患者术后均接受了以顺铂为基础的辅助化疗。在67例腹腔肿瘤局限于盆腔的患者中,14例因淋巴结阳性被分期为Ⅲ期(A组)。作者将A组患者的生存率与53例腹腔肿瘤局限于盆腔且淋巴结阴性的患者(B组)以及36例腹腔肿瘤超出盆腔(无论淋巴结状态如何)的患者(C组)的生存率进行了比较。
仅因淋巴结阳性而处于Ⅲ期的A组患者5年生存率相当不错,尽管与Ⅰ/Ⅱ期的B组患者相比无显著差异(84%对96%,P = 0.107)。A组的5年生存率比因腹腔肿瘤超出盆腔而被视为Ⅲ期的C组患者好得多(84%对26%,P = 0.042)。
对于腹腔肿瘤局限于盆腔且有淋巴结受累并接受系统性主动脉旁和盆腔淋巴结清扫术的患者,观察到相对较好的生存率。